SIETES :: 93061 citas

Resultados de la búsqueda por TRATAMIENTO REFINAR BÚSQUEDA

1.

Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, Brar I, Alangaden GJ, Ramesh MS, McKinnon JE, O'Neill W, Zervos M, Henry Ford COVID-19 Task Force. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. International Journal of Infectious Diseases 2020:1 de julio. [Ref.ID 103682]

2.

Moynihan R, MacDonald H, Bero L, Godlee F. Commercial influence and covid-19. BMJ 2020;369:24 de junio. [Ref.ID 103680]

3.

Mahase E. Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds. BMJ 2020;369:16 de junio. [Ref.ID 103675]

4.

Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, Metallidis S, Sianos G, Baltagiannis S, Panagopoulos P, et al.. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019. The GRECCO-19 randomized clinical trial. JAMA Network Open 2020;3:24 de junio. [Ref.ID 103674]

5.

Addis A, Ganazzani A, Trotta MP, Magrini N, for the Italian Medicines Agency Scientific Committee and COVID-19 Crisis Unit. Promoting better clinical trials and drug information as public health interventions for the COVID-19 emergency in Italy. Ann Intern Med 2020:16 de junio. [Ref.ID 103673]

6.

Taylor P. Gilead will test inhaled remdesivir in earlier-stage COVID-19. PMLiVE 2020:23 de junio. [Ref.ID 103672]

7.

Taylor P. COVID-19 round-up: WHO pulls hydroxychloroquine study, UK restricts dexamethasone exports, and more. PMLiVE 2020:19 de junio. [Ref.ID 103671]

8.

Samper E. Así afectan las prisas a la ciencia que rodea al coronavirus . eldiario.es 2020:23 de junio. [Ref.ID 103667]

9.

Rejón R. El 75% de los ensayos clínicos sobre COVID-19 en España son "no comerciales", pero eso no garantiza un acceso barato . eldiario.es 2020:20 de junio. [Ref.ID 103665]

10.

Anónimo. Remdesivir by Gilead Sciences: FDA warns of newly discovered potential drug interaction that may reduce effectiveness of treatment . U.S. Food and Drug Administration 2020:1. [Ref.ID 103664]

11.

Anónimo. Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine. U.S. Food and Drug Administration 2020:1. [Ref.ID 103663]

12.

Rome BN, Avorn J. Drug evaluation during the covid-19 pandemic. N Engl J Med 2020;382:11 de junio. [Ref.ID 103661]

13.

Taylor P. COVID-19 round-up: medicines on trial. PMLiVE 2020:9 de junio. [Ref.ID 103659]

14.

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020;369:14 de mayo. [Ref.ID 103652]

15.

Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, Fois E, Lepeule R, Szwebel T-A, Lescure F-X, Schlemmer F, Matignon M, Khellaf M, Crickx E, Terrier B, Morbieu C, Legendre P, Dang J, Schoindre Y, Pawlotsky J-M, Michel M, Perrodeau E, et al.. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:14 de mayo. [Ref.ID 103651]

16.

Fan-Ngai-Hung I, Lung K-C, Tso EY-K, Liu R, Chung TW-H, Chu M-Y, et al.. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet 2020;395:30 de mayo. [Ref.ID 103649]

17.

Borraz M, Ferrer S. Historia de un escándalo: una empresa sospechosa y el estudio que sacudió a la prestigiosa revista 'The Lancet' . eldiario.es 2020:6 de junio. [Ref.ID 103642]

18.

Wise J. Covid-19 and thrombosis: what do we know about the risks and treatment?. BMJ 2020;369:21 de mayo. [Ref.ID 103635]

19.

Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020:22 de mayo. [Ref.ID 103632]

20.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, et al. for the ACTT-1 Study Group Members. Remdesivir for the treatment of covid-19 — Preliminary report. N Engl J Med 2020:22 de mayo. [Ref.ID 103631]